Adderall – one of the most popular medications prescribed to treat attention deficit hyperactivity disorder – is in short supply, promoting the Food and Drug Administration to declare a nationwide shortage.

In a statement posted Oct. 12, the FDA said there was a shortage of amphetamine mixed salts, commonly referred to by the brand name Adderall or Adderall IR. The FDA said the shortages are due, in part, to “intermittent manufacturing delays,” at producer Teva. Other manufacturers continue to produce amphetamine mixed salts “but there is no sufficient supply to continue to meet U.S. market demand through those producers.”

“We will continue to monitor supply and assist manufacturers with anything needed to resolve the shortage and will update our website with new supply information as it becomes available,” the FDA said.

The shortage impacts multiple suppliers, including Epic Pharma, LLC., Lannett Company, Inc., Sandoz and Rhodes Pharmaceuticals L.P. Shortages could last until January 2023, the FDA said.

The shortages have hit community pharmacies particular hard. A survey by the National Community Pharmacists Association conducted July 25-Aug. 5 found that roughly 64% of 360 independent pharmacies reported difficulty obtaining Adderall.

Patients are advised to work with their healthcare providers to find alternatives if they are having trouble filling their ADHD prescriptions. You can also consult the list of current manufacturers and product strengths that are still available.